CB1, Gene Expression & Obesity

CB1, Gene Expression & Obesity

A new study from scientists at the University of South Carolina described how CB1 inhibition by Rimonabant leads to changes in gene regulation.
Abstract DNA strand

A synthetic cannabinoid pharmaceutical called Rimonabant was briefly approved in Europe as an anti-obesity drug. Rimonabant inhibits the CB1 receptor, reducing its activity below normal levels and blocking other compounds, like THC or anandamide, from activating it. It was taken off the market in 2008 for causing suicidal thoughts, among other psychiatric problems, which occurred when this pharmaceutical shut down cannabinoid activity in parts of the brain. Rimonabant is still a common tool for researchers studying the effect of CB1 inhibition, particularly in regard to obesity. A new study from scientists at the University of South Carolina described how CB1 inhibition by Rimonabant leads to changes in gene regulation, and a subsequent anti-obesity effect. The drug alters the level of immune-regulating microRNAs, which interfere with the ability of cells to make proteins from DNA, the universal genetic code. This mutes the effects of certain inflammatory genes, skewing immune cells to an anti-inflammatory state.

Find CBD near you

Browse hundreds of retail locations for quality CBD products.

Search

News & Reports

An oncologist and an osteopath discuss cannabis therapy for cancer patients.

Top Conditions

In compiling a list of conditions that CBD may help, we examined hundreds of peer-reviewed articles in scientific journals.

Cannabis Conversations

Project CBD talks with Dr. Bonni Goldstein about whole plant cannabis remedies, nonintoxicating cannabinoids, and cancer care for children.
Expert cannabis botanist and geneticist Ryan Lee talks to Project CBD about breeding cannabis, THC & CBD content, and how to interpret lab data.
Project CBD speaks with Dr. Rachel Knox about "endocannabinology," THC/CBD synergies, and whole food nutrition.

Top Stories